FDA panelists want suicidal-thought warning on ADHD drug

Several members of an FDA advisory panel asked the agency to change the labeling on Novartis' ($NVS) ADHD drug Focalin to reflect a risk of suicidal thoughts. An agency official pointed out, however, that only 8 reports about suicidal ideation have been filed during the 6 years since the drug was approved. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.